IFX-301
IgA Nephropathy (IgAN)
PreclinicalActive
Key Facts
About Infinimmune
Infinimmune is a private, preclinical-stage biotech leveraging a proprietary platform to discover and engineer human-derived antibodies. The company's approach centers on sequencing millions of paired antibody sequences from human B cells, using its Anthrobody library-on-B-cell platform and AI-driven GLIMPSE model to rapidly identify and optimize candidates. With a pipeline focused on immunology and inflammation, including a lead IL-22 inhibitor for atopic dermatitis in CMC stage, Infinimmune aims to translate natural human immune responses into novel biologics with superior safety and efficacy profiles.
View full company profileTherapeutic Areas
Other IgA Nephropathy (IgAN) Drugs
| Drug | Company | Phase |
|---|---|---|
| R1065 | Harbour BioMed | Discovery |
| TARPEYO (Nefecon) | Calliditas Therapeutics | Approved |
| TARPEYO (Nefecon) OLE | Calliditas Therapeutics | Phase 3 |
| KP104 | Kira Pharmaceuticals | Phase 2 |
| Atacicept | Vera Therapeutics | Phase 2b/3 |
| FILSPARI (sparsentan) | Travere Therapeutics | Approved |
| Telitacicept | Vor Biopharma | BLA Submitted |